Re: Cabergoline versus levodopa monotherapy: a decision analysis.
Marras
Connie
C
D000367:Age Factors; D000978:Antiparkinson Agents / Q000191:economics* / Q000627:therapeutic use*; D000077465:Cabergoline; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D004873:Ergolines / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000191:economics* / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics*; D011446:Prospective Studies; D011795:Surveys and Questionnaires
D000978:Antiparkinson Agents; D004873:Ergolines; D007980:Levodopa; D000077465:Cabergoline